Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02423980 · ClinicalTrials.gov registry record · Phase 2
G-Pen™ for Hypoglycemia Rescue in T1D Patients
A Phase 2 study of Hypoglycemia, sponsored by Xeris Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT02423980 is a Phase 2 study of Hypoglycemia that has completed, run by Xeris Pharmaceuticals. The registered enrollment target is 7 participants, below the 507-participant average among 40 other Hypoglycemia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02423980, a Phase 2 study of Hypoglycemia, has completed, sponsored by Xeris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, exploratory pilot study in patients with T1D. The study will involve two daytime clinical research center visits 7-14 days apart. Subjects will receive a single injection of G-Pen™ (glucagon injection) at each visit.
Conditions Studied
Interventions
- DRUG Glucagon
Study Locations (1)
California
- Diablo Clinical Research, Inc. - Walnut Creek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-04 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02423980
The ClinicalTrials.gov registry entry for NCT02423980 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 507-participant average among 40 other Hypoglycemia trials with a reported enrollment target (99% lower). The listed sponsor is Xeris Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypoglycemia appearing as the primary indexed condition, and to 1 intervention - of which Glucagon is the first listed.
NCT02423980 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02423980 about?
NCT02423980 is a clinical study titled "G-Pen™ for Hypoglycemia Rescue in T1D Patients". This is an open-label, exploratory pilot study in patients with T1D. The study will involve two daytime clinical research center visits 7-14 days apart. Subjects will receive a single injection of G-Pen™ (glucagon injection) at each visit.
What is the current status of trial NCT02423980?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2015-04. Estimated completion is 2015-06.
What conditions does trial NCT02423980 study?
This clinical trial studies the following conditions: Hypoglycemia.
What interventions are being tested in trial NCT02423980?
The interventions under investigation include: Glucagon (DRUG).
Who is sponsoring clinical trial NCT02423980?
This trial is sponsored by Xeris Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02423980 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoglycemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia
COMPLETED · Phase 2
-
Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients
COMPLETED · Phase 2
-
External Carotid Blood Flow in Individuals With Post-Bariatric Hypoglycemia
RECRUITING
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Diabetes Clinical Decision Support
RECRUITING · NA
-
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.